Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. Novacyt
  6. News
  7. Summary
    ALNOV   FR0010397232

NOVACYT

(ALNOV)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Novacyt : Launch of VersaLab™ Portable

05/26/2021 | 02:07am EDT

Paris, France and Camberley, UK - 26 May 2021 - Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces the expansion of its VersaLab™ portfolio with the launch of VersaLab™ Portable to provide an additional level of support in near-patient testing environments.

http://novacyt.com/wp-content/uploads/2021/05/Expansion-of-VersaLab-final-ENGLISH-.pdf

Disclaimer

Novacyt SA published this content on 26 May 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 26 May 2021 06:06:03 UTC.


© Publicnow 2021
All news about NOVACYT
06/29NOVACYT : Expansion of PathFlow® COVID-19 lateral flow test portfolio
PU
06/29NOVACYT : Rapport annuel et comptes Novacyt pour l'exercice clos en décembre 202..
PU
06/29Novacyt S.A. Announces Expansion of Pathflow Covid-19 Lateral Flow Test Portf..
CI
06/22GLOBAL MARKETS LIVE : Netflix, Boeing, Tesla, Delta Air Lines, Blackstone Resour..
06/22London Shares Trade Flat; Crude Gains Lift Oil Stocks
DJ
06/22NOVACYT : 2020 Management Report
PU
06/22NOVACYT : 2020 Group Consolidated Accounts
PU
06/22NOVACYT : Full year 2020 results and update on growth strategy
PU
06/22NOVACYT : Earnings Flash (NCYT.L) NOVACYT S.A. Posts FY20 Revenue GBP277.2M
MT
06/22NOVACYT : Earnings Flash (NCYT.L) NOVACYT S.A. Reports FY20 EPS GBP1.94
MT
More news
Financials
Sales 2021 95,4 M 112 M 112 M
Net income 2021 70,0 M 82,4 M 82,4 M
Net cash 2021 109 M 128 M 128 M
P/E ratio 2021 4,49x
Yield 2021 -
Capitalization 276 M 325 M 325 M
EV / Sales 2021 1,75x
EV / Sales 2022 1,02x
Nbr of Employees 174
Free-Float 99,2%
Chart NOVACYT
Duration : Period :
Novacyt Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NOVACYT
Short TermMid-TermLong Term
TrendsNeutralBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 2
Last Close Price 3,91 €
Average target price 8,88 €
Spread / Average Target 127%
EPS Revisions
Managers and Directors
Graham David Mullis Chief Executive Officer & Executive Director
James Martin Mccarthy Chief Financial Officer & Director
James Christopher Wakefield Chairman
R. A. Trevor Chief Technology Officer
Lisa Henriet Director-Group Operations
Sector and Competitors
1st jan.Capi. (M$)
NOVACYT-59.65%341
MODERNA, INC.209.64%88 312
GILEAD SCIENCES, INC.17.83%85 134
WUXI APPTEC CO., LTD.37.17%71 226
REGENERON PHARMACEUTICALS21.48%57 013
BIONTECH SE244.68%55 555